nodes	percent_of_prediction	percent_of_DWPC	metapath
Vidarabine—DPP4—exocrine gland—uterine cancer	0.0293	0.0762	CbGeAlD
Vidarabine—ADA—myometrium—uterine cancer	0.0205	0.0533	CbGeAlD
Vidarabine—ADK—myometrium—uterine cancer	0.0168	0.0435	CbGeAlD
Vidarabine—ADA—decidua—uterine cancer	0.0152	0.0395	CbGeAlD
Vidarabine—ADA—renal system—uterine cancer	0.0149	0.0388	CbGeAlD
Vidarabine—Cytarabine—POLD1—uterine cancer	0.0142	0.378	CrCbGaD
Vidarabine—ADA—mammalian vulva—uterine cancer	0.014	0.0363	CbGeAlD
Vidarabine—ADK—uterine cervix—uterine cancer	0.013	0.0339	CbGeAlD
Vidarabine—DPP4—epithelium—uterine cancer	0.0128	0.0331	CbGeAlD
Vidarabine—ADK—smooth muscle tissue—uterine cancer	0.0127	0.0329	CbGeAlD
Vidarabine—DPP4—uterine cervix—uterine cancer	0.0126	0.0328	CbGeAlD
Vidarabine—ADK—decidua—uterine cancer	0.0124	0.0323	CbGeAlD
Vidarabine—DPP4—smooth muscle tissue—uterine cancer	0.0123	0.0319	CbGeAlD
Vidarabine—ADK—renal system—uterine cancer	0.0122	0.0317	CbGeAlD
Vidarabine—DPP4—decidua—uterine cancer	0.012	0.0313	CbGeAlD
Vidarabine—ADA—female reproductive system—uterine cancer	0.012	0.0311	CbGeAlD
Vidarabine—DPP4—renal system—uterine cancer	0.0118	0.0307	CbGeAlD
Vidarabine—ADK—endometrium—uterine cancer	0.0118	0.0306	CbGeAlD
Vidarabine—DPP4—endometrium—uterine cancer	0.0114	0.0297	CbGeAlD
Vidarabine—ADK—mammalian vulva—uterine cancer	0.0114	0.0296	CbGeAlD
Vidarabine—DPP4—mammalian vulva—uterine cancer	0.0111	0.0287	CbGeAlD
Vidarabine—ADORA2A—female reproductive system—uterine cancer	0.0109	0.0283	CbGeAlD
Vidarabine—ADA—vagina—uterine cancer	0.0108	0.0281	CbGeAlD
Vidarabine—DPP4—uterus—uterine cancer	0.0105	0.0274	CbGeAlD
Vidarabine—ADK—female reproductive system—uterine cancer	0.00977	0.0254	CbGeAlD
Vidarabine—DPP4—female reproductive system—uterine cancer	0.00947	0.0246	CbGeAlD
Vidarabine—Clofarabine—RRM2—uterine cancer	0.00907	0.241	CrCbGaD
Vidarabine—ADK—female gonad—uterine cancer	0.00889	0.0231	CbGeAlD
Vidarabine—ADK—vagina—uterine cancer	0.00884	0.023	CbGeAlD
Vidarabine—DPP4—female gonad—uterine cancer	0.00862	0.0224	CbGeAlD
Vidarabine—DPP4—vagina—uterine cancer	0.00857	0.0223	CbGeAlD
Vidarabine—ADA—lymph node—uterine cancer	0.007	0.0182	CbGeAlD
Vidarabine—Adenosine triphosphate—ABCC9—uterine cancer	0.0061	0.162	CrCbGaD
Vidarabine—ADK—lymph node—uterine cancer	0.00572	0.0148	CbGeAlD
Vidarabine—DPP4—lymph node—uterine cancer	0.00554	0.0144	CbGeAlD
Vidarabine—Cladribine—RRM2—uterine cancer	0.00521	0.138	CrCbGaD
Vidarabine—Mood swings—Medroxyprogesterone Acetate—uterine cancer	0.00421	0.00814	CcSEcCtD
Vidarabine—Numbness—Etoposide—uterine cancer	0.00417	0.00806	CcSEcCtD
Vidarabine—Apnoea—Etoposide—uterine cancer	0.00408	0.00788	CcSEcCtD
Vidarabine—Abdominal discomfort—Progesterone—uterine cancer	0.00406	0.00785	CcSEcCtD
Vidarabine—Sensory loss—Etoposide—uterine cancer	0.00399	0.00771	CcSEcCtD
Vidarabine—Pain—Carboplatin—uterine cancer	0.00392	0.00758	CcSEcCtD
Vidarabine—Pollakiuria—Progesterone—uterine cancer	0.00392	0.00757	CcSEcCtD
Vidarabine—Chest discomfort—Etoposide—uterine cancer	0.00391	0.00755	CcSEcCtD
Vidarabine—Drowsiness—Progesterone—uterine cancer	0.00378	0.0073	CcSEcCtD
Vidarabine—Bronchospasm—Medroxyprogesterone Acetate—uterine cancer	0.00378	0.0073	CcSEcCtD
Vidarabine—Abdominal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00368	0.00712	CcSEcCtD
Vidarabine—ADK—Nucleotide metabolism—RRM2—uterine cancer	0.00361	0.0603	CbGpPWpGaD
Vidarabine—Pollakiuria—Medroxyprogesterone Acetate—uterine cancer	0.00355	0.00686	CcSEcCtD
Vidarabine—Drowsiness—Medroxyprogesterone Acetate—uterine cancer	0.00342	0.00662	CcSEcCtD
Vidarabine—DPP4—Peptide hormone metabolism—INHBA—uterine cancer	0.00342	0.0572	CbGpPWpGaD
Vidarabine—Acute coronary syndrome—Medroxyprogesterone Acetate—uterine cancer	0.00338	0.00652	CcSEcCtD
Vidarabine—Myocardial infarction—Medroxyprogesterone Acetate—uterine cancer	0.00336	0.00649	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—RNF43—uterine cancer	0.00331	0.0553	CbGpPWpGaD
Vidarabine—Sweating—Medroxyprogesterone Acetate—uterine cancer	0.00328	0.00634	CcSEcCtD
Vidarabine—DPP4—Peptide hormone metabolism—MME—uterine cancer	0.00322	0.0537	CbGpPWpGaD
Vidarabine—Tinnitus—Progesterone—uterine cancer	0.00316	0.00611	CcSEcCtD
Vidarabine—Cardiac disorder—Progesterone—uterine cancer	0.00315	0.00608	CcSEcCtD
Vidarabine—Bradycardia—Medroxyprogesterone Acetate—uterine cancer	0.00313	0.00605	CcSEcCtD
Vidarabine—Mediastinal disorder—Progesterone—uterine cancer	0.00306	0.00591	CcSEcCtD
Vidarabine—Adenosine triphosphate—AKT1—uterine cancer	0.00302	0.0803	CrCbGaD
Vidarabine—Tension—Progesterone—uterine cancer	0.0029	0.0056	CcSEcCtD
Vidarabine—Nervousness—Progesterone—uterine cancer	0.00287	0.00554	CcSEcCtD
Vidarabine—Tinnitus—Medroxyprogesterone Acetate—uterine cancer	0.00287	0.00554	CcSEcCtD
Vidarabine—Back pain—Progesterone—uterine cancer	0.00286	0.00552	CcSEcCtD
Vidarabine—Cardiac disorder—Medroxyprogesterone Acetate—uterine cancer	0.00285	0.00551	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—FBXW7—uterine cancer	0.00283	0.0473	CbGpPWpGaD
Vidarabine—Hyperventilation—Epirubicin—uterine cancer	0.00282	0.00544	CcSEcCtD
Vidarabine—Burning sensation—Epirubicin—uterine cancer	0.00279	0.00539	CcSEcCtD
Vidarabine—Vision blurred—Progesterone—uterine cancer	0.00278	0.00538	CcSEcCtD
Vidarabine—Mediastinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00277	0.00535	CcSEcCtD
Vidarabine—Tremor—Progesterone—uterine cancer	0.00277	0.00535	CcSEcCtD
Vidarabine—Angioedema—Progesterone—uterine cancer	0.0027	0.00522	CcSEcCtD
Vidarabine—Syncope—Progesterone—uterine cancer	0.00265	0.00512	CcSEcCtD
Vidarabine—DPP4—Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)—CTNNB1—uterine cancer	0.00263	0.0439	CbGpPWpGaD
Vidarabine—Tension—Medroxyprogesterone Acetate—uterine cancer	0.00263	0.00508	CcSEcCtD
Vidarabine—Dysgeusia—Medroxyprogesterone Acetate—uterine cancer	0.00262	0.00506	CcSEcCtD
Vidarabine—Ventricular arrhythmia—Epirubicin—uterine cancer	0.00262	0.00506	CcSEcCtD
Vidarabine—Palpitations—Progesterone—uterine cancer	0.00261	0.00504	CcSEcCtD
Vidarabine—Hyperventilation—Doxorubicin—uterine cancer	0.0026	0.00503	CcSEcCtD
Vidarabine—Nervousness—Medroxyprogesterone Acetate—uterine cancer	0.0026	0.00502	CcSEcCtD
Vidarabine—Loss of consciousness—Progesterone—uterine cancer	0.0026	0.00502	CcSEcCtD
Vidarabine—Back pain—Medroxyprogesterone Acetate—uterine cancer	0.00259	0.005	CcSEcCtD
Vidarabine—Burning sensation—Doxorubicin—uterine cancer	0.00258	0.00499	CcSEcCtD
Vidarabine—Cough—Progesterone—uterine cancer	0.00258	0.00498	CcSEcCtD
Vidarabine—Cardiac failure—Etoposide—uterine cancer	0.00257	0.00497	CcSEcCtD
Vidarabine—Convulsion—Progesterone—uterine cancer	0.00256	0.00495	CcSEcCtD
Vidarabine—Scotoma—Epirubicin—uterine cancer	0.00255	0.00493	CcSEcCtD
Vidarabine—Hypertension—Progesterone—uterine cancer	0.00255	0.00493	CcSEcCtD
Vidarabine—Chest pain—Progesterone—uterine cancer	0.00251	0.00486	CcSEcCtD
Vidarabine—Tremor—Medroxyprogesterone Acetate—uterine cancer	0.00251	0.00485	CcSEcCtD
Vidarabine—Anxiety—Progesterone—uterine cancer	0.00251	0.00484	CcSEcCtD
Vidarabine—Discomfort—Progesterone—uterine cancer	0.00248	0.0048	CcSEcCtD
Vidarabine—Agitation—Medroxyprogesterone Acetate—uterine cancer	0.00246	0.00475	CcSEcCtD
Vidarabine—Dry mouth—Progesterone—uterine cancer	0.00246	0.00475	CcSEcCtD
Vidarabine—ADA—Nucleotide metabolism—RRM2—uterine cancer	0.00245	0.041	CbGpPWpGaD
Vidarabine—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.00245	0.00473	CcSEcCtD
Vidarabine—Ventricular arrhythmia—Doxorubicin—uterine cancer	0.00242	0.00468	CcSEcCtD
Vidarabine—Anaphylactic shock—Progesterone—uterine cancer	0.00241	0.00466	CcSEcCtD
Vidarabine—Syncope—Medroxyprogesterone Acetate—uterine cancer	0.0024	0.00464	CcSEcCtD
Vidarabine—Cardiac arrest—Etoposide—uterine cancer	0.00239	0.00461	CcSEcCtD
Vidarabine—Shock—Progesterone—uterine cancer	0.00237	0.00458	CcSEcCtD
Vidarabine—Palpitations—Medroxyprogesterone Acetate—uterine cancer	0.00237	0.00457	CcSEcCtD
Vidarabine—Scotoma—Doxorubicin—uterine cancer	0.00236	0.00456	CcSEcCtD
Vidarabine—Tachycardia—Progesterone—uterine cancer	0.00235	0.00455	CcSEcCtD
Vidarabine—Loss of consciousness—Medroxyprogesterone Acetate—uterine cancer	0.00235	0.00455	CcSEcCtD
Vidarabine—DPP4—Incretin synthesis, secretion, and inactivation—CTNNB1—uterine cancer	0.00234	0.039	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Progesterone—uterine cancer	0.00233	0.0045	CcSEcCtD
Vidarabine—Convulsion—Medroxyprogesterone Acetate—uterine cancer	0.00232	0.00448	CcSEcCtD
Vidarabine—Chest pain—Medroxyprogesterone Acetate—uterine cancer	0.00228	0.0044	CcSEcCtD
Vidarabine—Anxiety—Medroxyprogesterone Acetate—uterine cancer	0.00227	0.00439	CcSEcCtD
Vidarabine—Hypotension—Progesterone—uterine cancer	0.00225	0.00435	CcSEcCtD
Vidarabine—Discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00225	0.00435	CcSEcCtD
Vidarabine—Dry mouth—Medroxyprogesterone Acetate—uterine cancer	0.00223	0.00431	CcSEcCtD
Vidarabine—Flushing—Dactinomycin—uterine cancer	0.00223	0.0043	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Progesterone—uterine cancer	0.0022	0.00424	CcSEcCtD
Vidarabine—Anaphylactic shock—Medroxyprogesterone Acetate—uterine cancer	0.00218	0.00422	CcSEcCtD
Vidarabine—Paraesthesia—Progesterone—uterine cancer	0.00216	0.00418	CcSEcCtD
Vidarabine—Dyspnoea—Progesterone—uterine cancer	0.00215	0.00415	CcSEcCtD
Vidarabine—Shock—Medroxyprogesterone Acetate—uterine cancer	0.00215	0.00415	CcSEcCtD
Vidarabine—Ventricular extrasystoles—Epirubicin—uterine cancer	0.00214	0.00414	CcSEcCtD
Vidarabine—Somnolence—Progesterone—uterine cancer	0.00214	0.00414	CcSEcCtD
Vidarabine—Bronchospasm—Etoposide—uterine cancer	0.00213	0.00412	CcSEcCtD
Vidarabine—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.00213	0.00412	CcSEcCtD
Vidarabine—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.00211	0.00408	CcSEcCtD
Vidarabine—Pain—Progesterone—uterine cancer	0.00206	0.00398	CcSEcCtD
Vidarabine—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.00204	0.00394	CcSEcCtD
Vidarabine—Atrioventricular block—Epirubicin—uterine cancer	0.002	0.00386	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Medroxyprogesterone Acetate—uterine cancer	0.00199	0.00385	CcSEcCtD
Vidarabine—Ventricular extrasystoles—Doxorubicin—uterine cancer	0.00198	0.00384	CcSEcCtD
Vidarabine—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.00196	0.00379	CcSEcCtD
Vidarabine—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.00195	0.00376	CcSEcCtD
Vidarabine—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.00194	0.00375	CcSEcCtD
Vidarabine—Ventricular tachycardia—Epirubicin—uterine cancer	0.00194	0.00374	CcSEcCtD
Vidarabine—Injection site reaction—Epirubicin—uterine cancer	0.00193	0.00372	CcSEcCtD
Vidarabine—Urticaria—Progesterone—uterine cancer	0.00191	0.0037	CcSEcCtD
Vidarabine—Acute coronary syndrome—Etoposide—uterine cancer	0.00191	0.00368	CcSEcCtD
Vidarabine—Myocardial infarction—Etoposide—uterine cancer	0.0019	0.00366	CcSEcCtD
Vidarabine—Atrioventricular block—Doxorubicin—uterine cancer	0.00185	0.00357	CcSEcCtD
Vidarabine—Ventricular tachycardia—Doxorubicin—uterine cancer	0.00179	0.00346	CcSEcCtD
Vidarabine—Injection site reaction—Doxorubicin—uterine cancer	0.00178	0.00344	CcSEcCtD
Vidarabine—Hypersensitivity—Progesterone—uterine cancer	0.00178	0.00343	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—STAR—uterine cancer	0.00176	0.0294	CbGpPWpGaD
Vidarabine—Discomfort—Dactinomycin—uterine cancer	0.00176	0.00339	CcSEcCtD
Vidarabine—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.00174	0.00335	CcSEcCtD
Vidarabine—Asthenia—Progesterone—uterine cancer	0.00173	0.00334	CcSEcCtD
Vidarabine—Hypoaesthesia—Etoposide—uterine cancer	0.00173	0.00334	CcSEcCtD
Vidarabine—Cardiac disorder—Etoposide—uterine cancer	0.00161	0.00311	CcSEcCtD
Vidarabine—Flushing—Etoposide—uterine cancer	0.00161	0.00311	CcSEcCtD
Vidarabine—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.00161	0.00311	CcSEcCtD
Vidarabine—Dizziness—Progesterone—uterine cancer	0.00159	0.00308	CcSEcCtD
Vidarabine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.00157	0.00303	CcSEcCtD
Vidarabine—Mediastinal disorder—Etoposide—uterine cancer	0.00156	0.00302	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Dactinomycin—uterine cancer	0.00155	0.003	CcSEcCtD
Vidarabine—Vomiting—Progesterone—uterine cancer	0.00153	0.00296	CcSEcCtD
Vidarabine—Rash—Progesterone—uterine cancer	0.00152	0.00294	CcSEcCtD
Vidarabine—Dermatitis—Progesterone—uterine cancer	0.00152	0.00293	CcSEcCtD
Vidarabine—Headache—Progesterone—uterine cancer	0.00151	0.00292	CcSEcCtD
Vidarabine—Dysgeusia—Etoposide—uterine cancer	0.00148	0.00286	CcSEcCtD
Vidarabine—Back pain—Etoposide—uterine cancer	0.00146	0.00282	CcSEcCtD
Vidarabine—Pain—Dactinomycin—uterine cancer	0.00146	0.00282	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—TSPYL2—uterine cancer	0.00145	0.0242	CbGpPWpGaD
Vidarabine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00144	0.00279	CcSEcCtD
Vidarabine—Cardiac failure—Epirubicin—uterine cancer	0.00144	0.00278	CcSEcCtD
Vidarabine—Cerebrovascular accident—Epirubicin—uterine cancer	0.00144	0.00277	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—HNF1B—uterine cancer	0.00143	0.0239	CbGpPWpGaD
Vidarabine—Nausea—Progesterone—uterine cancer	0.00143	0.00277	CcSEcCtD
Vidarabine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.00139	0.00268	CcSEcCtD
Vidarabine—Affect lability—Epirubicin—uterine cancer	0.00138	0.00267	CcSEcCtD
Vidarabine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.00138	0.00266	CcSEcCtD
Vidarabine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.00138	0.00266	CcSEcCtD
Vidarabine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00137	0.00264	CcSEcCtD
Vidarabine—Cardiac arrest—Epirubicin—uterine cancer	0.00134	0.00258	CcSEcCtD
Vidarabine—Cardiac failure—Doxorubicin—uterine cancer	0.00133	0.00258	CcSEcCtD
Vidarabine—Mood swings—Epirubicin—uterine cancer	0.00133	0.00257	CcSEcCtD
Vidarabine—Loss of consciousness—Etoposide—uterine cancer	0.00133	0.00257	CcSEcCtD
Vidarabine—Cerebrovascular accident—Doxorubicin—uterine cancer	0.00133	0.00257	CcSEcCtD
Vidarabine—Cough—Etoposide—uterine cancer	0.00132	0.00255	CcSEcCtD
Vidarabine—Convulsion—Etoposide—uterine cancer	0.00131	0.00253	CcSEcCtD
Vidarabine—Hypertension—Etoposide—uterine cancer	0.0013	0.00252	CcSEcCtD
Vidarabine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.0013	0.00251	CcSEcCtD
Vidarabine—Chest pain—Etoposide—uterine cancer	0.00129	0.00249	CcSEcCtD
Vidarabine—Affect lability—Doxorubicin—uterine cancer	0.00128	0.00248	CcSEcCtD
Vidarabine—Discomfort—Etoposide—uterine cancer	0.00127	0.00246	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—uterine cancer	0.00127	0.0212	CbGpPWpGaD
Vidarabine—Hypersensitivity—Dactinomycin—uterine cancer	0.00126	0.00243	CcSEcCtD
Vidarabine—Cardiac arrest—Doxorubicin—uterine cancer	0.00124	0.00239	CcSEcCtD
Vidarabine—Anaphylactic shock—Etoposide—uterine cancer	0.00123	0.00238	CcSEcCtD
Vidarabine—Mood swings—Doxorubicin—uterine cancer	0.00123	0.00238	CcSEcCtD
Vidarabine—Asthenia—Dactinomycin—uterine cancer	0.00122	0.00236	CcSEcCtD
Vidarabine—Tachycardia—Etoposide—uterine cancer	0.0012	0.00233	CcSEcCtD
Vidarabine—Hyperhidrosis—Etoposide—uterine cancer	0.00119	0.0023	CcSEcCtD
Vidarabine—Hypotension—Etoposide—uterine cancer	0.00115	0.00223	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—CDKN2A—uterine cancer	0.00114	0.019	CbGpPWpGaD
Vidarabine—Pollakiuria—Epirubicin—uterine cancer	0.00112	0.00217	CcSEcCtD
Vidarabine—Paraesthesia—Etoposide—uterine cancer	0.00111	0.00214	CcSEcCtD
Vidarabine—Dyspnoea—Etoposide—uterine cancer	0.0011	0.00212	CcSEcCtD
Vidarabine—Somnolence—Etoposide—uterine cancer	0.0011	0.00212	CcSEcCtD
Vidarabine—Drowsiness—Epirubicin—uterine cancer	0.00108	0.00209	CcSEcCtD
Vidarabine—Vomiting—Dactinomycin—uterine cancer	0.00108	0.00209	CcSEcCtD
Vidarabine—Rash—Dactinomycin—uterine cancer	0.00107	0.00208	CcSEcCtD
Vidarabine—Pain—Etoposide—uterine cancer	0.00105	0.00204	CcSEcCtD
Vidarabine—Sweating—Epirubicin—uterine cancer	0.00104	0.00201	CcSEcCtD
Vidarabine—Pollakiuria—Doxorubicin—uterine cancer	0.00104	0.00201	CcSEcCtD
Vidarabine—Nausea—Dactinomycin—uterine cancer	0.00101	0.00196	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—STAR—uterine cancer	0.00101	0.0169	CbGpPWpGaD
Vidarabine—Drowsiness—Doxorubicin—uterine cancer	0.001	0.00194	CcSEcCtD
Vidarabine—Bradycardia—Epirubicin—uterine cancer	0.00099	0.00191	CcSEcCtD
Vidarabine—Urticaria—Etoposide—uterine cancer	0.00098	0.00189	CcSEcCtD
Vidarabine—Hypoaesthesia—Epirubicin—uterine cancer	0.000968	0.00187	CcSEcCtD
Vidarabine—Sweating—Doxorubicin—uterine cancer	0.000961	0.00186	CcSEcCtD
Vidarabine—ADA—Circadian rythm related genes—EZH2—uterine cancer	0.00092	0.0154	CbGpPWpGaD
Vidarabine—Bradycardia—Doxorubicin—uterine cancer	0.000916	0.00177	CcSEcCtD
Vidarabine—Hypersensitivity—Etoposide—uterine cancer	0.000909	0.00176	CcSEcCtD
Vidarabine—Tinnitus—Epirubicin—uterine cancer	0.000907	0.00175	CcSEcCtD
Vidarabine—Flushing—Epirubicin—uterine cancer	0.000903	0.00174	CcSEcCtD
Vidarabine—Cardiac disorder—Epirubicin—uterine cancer	0.000903	0.00174	CcSEcCtD
Vidarabine—Hypoaesthesia—Doxorubicin—uterine cancer	0.000896	0.00173	CcSEcCtD
Vidarabine—Asthenia—Etoposide—uterine cancer	0.000885	0.00171	CcSEcCtD
Vidarabine—ADA—Validated transcriptional targets of TAp63 isoforms—EP300—uterine cancer	0.000884	0.0147	CbGpPWpGaD
Vidarabine—Mediastinal disorder—Epirubicin—uterine cancer	0.000877	0.00169	CcSEcCtD
Vidarabine—Arrhythmia—Epirubicin—uterine cancer	0.000869	0.00168	CcSEcCtD
Vidarabine—Tinnitus—Doxorubicin—uterine cancer	0.000839	0.00162	CcSEcCtD
Vidarabine—Cardiac disorder—Doxorubicin—uterine cancer	0.000835	0.00161	CcSEcCtD
Vidarabine—Flushing—Doxorubicin—uterine cancer	0.000835	0.00161	CcSEcCtD
Vidarabine—Tension—Epirubicin—uterine cancer	0.000831	0.00161	CcSEcCtD
Vidarabine—Dysgeusia—Epirubicin—uterine cancer	0.000829	0.0016	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—HNF1B—uterine cancer	0.000824	0.0137	CbGpPWpGaD
Vidarabine—Nervousness—Epirubicin—uterine cancer	0.000823	0.00159	CcSEcCtD
Vidarabine—Back pain—Epirubicin—uterine cancer	0.000819	0.00158	CcSEcCtD
Vidarabine—Dizziness—Etoposide—uterine cancer	0.000815	0.00158	CcSEcCtD
Vidarabine—Mediastinal disorder—Doxorubicin—uterine cancer	0.000811	0.00157	CcSEcCtD
Vidarabine—Arrhythmia—Doxorubicin—uterine cancer	0.000804	0.00155	CcSEcCtD
Vidarabine—Vision blurred—Epirubicin—uterine cancer	0.000798	0.00154	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CDKN2A—uterine cancer	0.000798	0.0133	CbGpPWpGaD
Vidarabine—DPP4—Peptide hormone metabolism—CTNNB1—uterine cancer	0.000793	0.0132	CbGpPWpGaD
Vidarabine—Vomiting—Etoposide—uterine cancer	0.000784	0.00152	CcSEcCtD
Vidarabine—Agitation—Epirubicin—uterine cancer	0.000778	0.0015	CcSEcCtD
Vidarabine—Rash—Etoposide—uterine cancer	0.000778	0.0015	CcSEcCtD
Vidarabine—Dermatitis—Etoposide—uterine cancer	0.000777	0.0015	CcSEcCtD
Vidarabine—Headache—Etoposide—uterine cancer	0.000773	0.00149	CcSEcCtD
Vidarabine—Tension—Doxorubicin—uterine cancer	0.000769	0.00149	CcSEcCtD
Vidarabine—Dysgeusia—Doxorubicin—uterine cancer	0.000767	0.00148	CcSEcCtD
Vidarabine—Nervousness—Doxorubicin—uterine cancer	0.000761	0.00147	CcSEcCtD
Vidarabine—Syncope—Epirubicin—uterine cancer	0.00076	0.00147	CcSEcCtD
Vidarabine—Back pain—Doxorubicin—uterine cancer	0.000758	0.00146	CcSEcCtD
Vidarabine—Palpitations—Epirubicin—uterine cancer	0.000748	0.00145	CcSEcCtD
Vidarabine—Loss of consciousness—Epirubicin—uterine cancer	0.000744	0.00144	CcSEcCtD
Vidarabine—Cough—Epirubicin—uterine cancer	0.000739	0.00143	CcSEcCtD
Vidarabine—Vision blurred—Doxorubicin—uterine cancer	0.000739	0.00143	CcSEcCtD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—EP300—uterine cancer	0.000735	0.0123	CbGpPWpGaD
Vidarabine—Convulsion—Epirubicin—uterine cancer	0.000734	0.00142	CcSEcCtD
Vidarabine—Nausea—Etoposide—uterine cancer	0.000732	0.00142	CcSEcCtD
Vidarabine—Hypertension—Epirubicin—uterine cancer	0.000731	0.00141	CcSEcCtD
Vidarabine—Chest pain—Epirubicin—uterine cancer	0.000721	0.00139	CcSEcCtD
Vidarabine—Agitation—Doxorubicin—uterine cancer	0.00072	0.00139	CcSEcCtD
Vidarabine—Anxiety—Epirubicin—uterine cancer	0.000719	0.00139	CcSEcCtD
Vidarabine—Discomfort—Epirubicin—uterine cancer	0.000712	0.00138	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—CDKN1B—uterine cancer	0.000707	0.0118	CbGpPWpGaD
Vidarabine—Dry mouth—Epirubicin—uterine cancer	0.000705	0.00136	CcSEcCtD
Vidarabine—Syncope—Doxorubicin—uterine cancer	0.000703	0.00136	CcSEcCtD
Vidarabine—ADORA2A—HIF-2-alpha transcription factor network—VEGFA—uterine cancer	0.000696	0.0116	CbGpPWpGaD
Vidarabine—ADK—Metabolism—NDUFB11—uterine cancer	0.000693	0.0116	CbGpPWpGaD
Vidarabine—ADK—Metabolism—SRD5A2—uterine cancer	0.000693	0.0116	CbGpPWpGaD
Vidarabine—Palpitations—Doxorubicin—uterine cancer	0.000693	0.00134	CcSEcCtD
Vidarabine—Anaphylactic shock—Epirubicin—uterine cancer	0.000691	0.00134	CcSEcCtD
Vidarabine—Loss of consciousness—Doxorubicin—uterine cancer	0.000689	0.00133	CcSEcCtD
Vidarabine—Cough—Doxorubicin—uterine cancer	0.000684	0.00132	CcSEcCtD
Vidarabine—Shock—Epirubicin—uterine cancer	0.00068	0.00131	CcSEcCtD
Vidarabine—Convulsion—Doxorubicin—uterine cancer	0.000679	0.00131	CcSEcCtD
Vidarabine—Hypertension—Doxorubicin—uterine cancer	0.000677	0.00131	CcSEcCtD
Vidarabine—Tachycardia—Epirubicin—uterine cancer	0.000675	0.0013	CcSEcCtD
Vidarabine—Hyperhidrosis—Epirubicin—uterine cancer	0.000668	0.00129	CcSEcCtD
Vidarabine—Chest pain—Doxorubicin—uterine cancer	0.000667	0.00129	CcSEcCtD
Vidarabine—Anxiety—Doxorubicin—uterine cancer	0.000665	0.00128	CcSEcCtD
Vidarabine—Discomfort—Doxorubicin—uterine cancer	0.000659	0.00127	CcSEcCtD
Vidarabine—Dry mouth—Doxorubicin—uterine cancer	0.000652	0.00126	CcSEcCtD
Vidarabine—ADA—p73 transcription factor network—EP300—uterine cancer	0.000652	0.0109	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—INHBA—uterine cancer	0.000646	0.0108	CbGpPWpGaD
Vidarabine—Hypotension—Epirubicin—uterine cancer	0.000646	0.00125	CcSEcCtD
Vidarabine—Anaphylactic shock—Doxorubicin—uterine cancer	0.00064	0.00124	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Epirubicin—uterine cancer	0.00063	0.00122	CcSEcCtD
Vidarabine—Shock—Doxorubicin—uterine cancer	0.000629	0.00122	CcSEcCtD
Vidarabine—Tachycardia—Doxorubicin—uterine cancer	0.000624	0.00121	CcSEcCtD
Vidarabine—Paraesthesia—Epirubicin—uterine cancer	0.000621	0.0012	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—EP300—uterine cancer	0.000621	0.0104	CbGpPWpGaD
Vidarabine—Hyperhidrosis—Doxorubicin—uterine cancer	0.000618	0.00119	CcSEcCtD
Vidarabine—Dyspnoea—Epirubicin—uterine cancer	0.000616	0.00119	CcSEcCtD
Vidarabine—Somnolence—Epirubicin—uterine cancer	0.000615	0.00119	CcSEcCtD
Vidarabine—DPP4—Metabolism of proteins—MME—uterine cancer	0.000608	0.0101	CbGpPWpGaD
Vidarabine—Hypotension—Doxorubicin—uterine cancer	0.000598	0.00115	CcSEcCtD
Vidarabine—Pain—Epirubicin—uterine cancer	0.000591	0.00114	CcSEcCtD
Vidarabine—Musculoskeletal discomfort—Doxorubicin—uterine cancer	0.000583	0.00113	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—NRAS—uterine cancer	0.000581	0.00969	CbGpPWpGaD
Vidarabine—Paraesthesia—Doxorubicin—uterine cancer	0.000574	0.00111	CcSEcCtD
Vidarabine—Dyspnoea—Doxorubicin—uterine cancer	0.00057	0.0011	CcSEcCtD
Vidarabine—Somnolence—Doxorubicin—uterine cancer	0.000569	0.0011	CcSEcCtD
Vidarabine—Urticaria—Epirubicin—uterine cancer	0.000549	0.00106	CcSEcCtD
Vidarabine—Pain—Doxorubicin—uterine cancer	0.000547	0.00106	CcSEcCtD
Vidarabine—ADORA2A—Circadian rythm related genes—EZH2—uterine cancer	0.000528	0.00882	CbGpPWpGaD
Vidarabine—Hypersensitivity—Epirubicin—uterine cancer	0.000509	0.000984	CcSEcCtD
Vidarabine—Urticaria—Doxorubicin—uterine cancer	0.000508	0.000982	CcSEcCtD
Vidarabine—ADK—Metabolism—STAR—uterine cancer	0.000501	0.00837	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AKR1B1—uterine cancer	0.000501	0.00837	CbGpPWpGaD
Vidarabine—ADA—C-MYB transcription factor network—KRAS—uterine cancer	0.0005	0.00834	CbGpPWpGaD
Vidarabine—Asthenia—Epirubicin—uterine cancer	0.000496	0.000958	CcSEcCtD
Vidarabine—ADA—Metabolism—SRD5A2—uterine cancer	0.000471	0.00787	CbGpPWpGaD
Vidarabine—ADA—Metabolism—NDUFB11—uterine cancer	0.000471	0.00787	CbGpPWpGaD
Vidarabine—Hypersensitivity—Doxorubicin—uterine cancer	0.000471	0.000911	CcSEcCtD
Vidarabine—Asthenia—Doxorubicin—uterine cancer	0.000459	0.000887	CcSEcCtD
Vidarabine—Dizziness—Epirubicin—uterine cancer	0.000457	0.000883	CcSEcCtD
Vidarabine—Vomiting—Epirubicin—uterine cancer	0.000439	0.000849	CcSEcCtD
Vidarabine—Rash—Epirubicin—uterine cancer	0.000436	0.000842	CcSEcCtD
Vidarabine—Dermatitis—Epirubicin—uterine cancer	0.000435	0.000841	CcSEcCtD
Vidarabine—Headache—Epirubicin—uterine cancer	0.000433	0.000837	CcSEcCtD
Vidarabine—ADA—C-MYB transcription factor network—HRAS—uterine cancer	0.000425	0.00709	CbGpPWpGaD
Vidarabine—Dizziness—Doxorubicin—uterine cancer	0.000423	0.000817	CcSEcCtD
Vidarabine—Nausea—Epirubicin—uterine cancer	0.000411	0.000793	CcSEcCtD
Vidarabine—Vomiting—Doxorubicin—uterine cancer	0.000407	0.000786	CcSEcCtD
Vidarabine—Rash—Doxorubicin—uterine cancer	0.000403	0.000779	CcSEcCtD
Vidarabine—Dermatitis—Doxorubicin—uterine cancer	0.000403	0.000779	CcSEcCtD
Vidarabine—Headache—Doxorubicin—uterine cancer	0.000401	0.000774	CcSEcCtD
Vidarabine—ADORA2A—Signaling by NGF—YWHAE—uterine cancer	0.0004	0.00668	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—FBXW7—uterine cancer	0.000399	0.00667	CbGpPWpGaD
Vidarabine—ADK—Metabolism—POLD1—uterine cancer	0.000393	0.00657	CbGpPWpGaD
Vidarabine—Nausea—Doxorubicin—uterine cancer	0.00038	0.000734	CcSEcCtD
Vidarabine—ADK—Metabolism—AKR1C1—uterine cancer	0.000368	0.00614	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKR1B1—uterine cancer	0.000341	0.00569	CbGpPWpGaD
Vidarabine—ADA—Metabolism—STAR—uterine cancer	0.000341	0.00569	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—FGFR2—uterine cancer	0.00034	0.00568	CbGpPWpGaD
Vidarabine—ADK—Metabolism—RRM2—uterine cancer	0.000328	0.00548	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—PTEN—uterine cancer	0.000324	0.0054	CbGpPWpGaD
Vidarabine—ADK—Metabolism—DCN—uterine cancer	0.000318	0.00532	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—EP300—uterine cancer	0.000309	0.00515	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP11A1—uterine cancer	0.0003	0.00501	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AKR1C3—uterine cancer	0.000283	0.00473	CbGpPWpGaD
Vidarabine—ADA—Metabolism—POLD1—uterine cancer	0.000267	0.00446	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—FGFR2—uterine cancer	0.000262	0.00437	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKR1C1—uterine cancer	0.00025	0.00418	CbGpPWpGaD
Vidarabine—ADA—Metabolism—RRM2—uterine cancer	0.000223	0.00372	CbGpPWpGaD
Vidarabine—ADA—Circadian rythm related genes—TP53—uterine cancer	0.000221	0.00369	CbGpPWpGaD
Vidarabine—ADK—Metabolism—CYP19A1—uterine cancer	0.000221	0.00368	CbGpPWpGaD
Vidarabine—ADK—Metabolism—STK11—uterine cancer	0.000221	0.00368	CbGpPWpGaD
Vidarabine—ADA—Metabolism—DCN—uterine cancer	0.000216	0.00361	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—ERBB2—uterine cancer	0.000214	0.00357	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CCL2—uterine cancer	0.000205	0.00343	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP11A1—uterine cancer	0.000204	0.0034	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—CDKN1B—uterine cancer	0.000198	0.00331	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKR1C3—uterine cancer	0.000193	0.00321	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—PTEN—uterine cancer	0.000186	0.0031	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	0.000184	0.00306	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PTEN—uterine cancer	0.000182	0.00304	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—EP300—uterine cancer	0.000177	0.00296	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKR1B10—uterine cancer	0.000176	0.00294	CbGpPWpGaD
Vidarabine—ADK—Metabolism—MTHFR—uterine cancer	0.000166	0.00277	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—ERBB2—uterine cancer	0.000164	0.00275	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—NRAS—uterine cancer	0.000163	0.00272	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CXCL8—uterine cancer	0.000162	0.00271	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—CDKN1B—uterine cancer	0.000152	0.00254	CbGpPWpGaD
Vidarabine—ADA—Metabolism—STK11—uterine cancer	0.00015	0.0025	CbGpPWpGaD
Vidarabine—ADA—Metabolism—CYP19A1—uterine cancer	0.00015	0.0025	CbGpPWpGaD
Vidarabine—DPP4—Metabolism of proteins—CTNNB1—uterine cancer	0.00015	0.0025	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—RNF43—uterine cancer	0.000146	0.00244	CbGpPWpGaD
Vidarabine—ADORA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	0.000145	0.00242	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PTEN—uterine cancer	0.00014	0.00234	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—KRAS—uterine cancer	0.00014	0.00234	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CCL2—uterine cancer	0.00014	0.00233	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—INHBA—uterine cancer	0.000133	0.00223	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—PIK3CA—uterine cancer	0.000129	0.00215	CbGpPWpGaD
Vidarabine—ADORA2A—Circadian rythm related genes—TP53—uterine cancer	0.000127	0.00212	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—NRAS—uterine cancer	0.000125	0.00209	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKR1C1—uterine cancer	0.00012	0.00201	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—HRAS—uterine cancer	0.000119	0.00199	CbGpPWpGaD
Vidarabine—ADA—Metabolism—MTHFR—uterine cancer	0.000113	0.00188	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR ligand binding—CXCL8—uterine cancer	0.00011	0.00184	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—KRAS—uterine cancer	0.000108	0.0018	CbGpPWpGaD
Vidarabine—ADORA2A—NGF signalling via TRKA from the plasma membrane—AKT1—uterine cancer	0.000105	0.00175	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—PIK3CA—uterine cancer	9.89e-05	0.00165	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKR1C3—uterine cancer	9.25e-05	0.00154	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PTEN—uterine cancer	9.23e-05	0.00154	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—HRAS—uterine cancer	9.15e-05	0.00153	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PGR—uterine cancer	9.01e-05	0.0015	CbGpPWpGaD
Vidarabine—ADK—Metabolism—EP300—uterine cancer	8.8e-05	0.00147	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—YWHAE—uterine cancer	8.6e-05	0.00144	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FBXW7—uterine cancer	8.24e-05	0.00138	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by NGF—AKT1—uterine cancer	8.08e-05	0.00135	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—STK11—uterine cancer	7.21e-05	0.0012	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CCL2—uterine cancer	7.17e-05	0.0012	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SOCS3—uterine cancer	6.75e-05	0.00113	CbGpPWpGaD
Vidarabine—ADK—Metabolism—PIK3CA—uterine cancer	6.51e-05	0.00109	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN2B—uterine cancer	6.46e-05	0.00108	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—IGF1R—uterine cancer	6.27e-05	0.00105	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PTEN—uterine cancer	6.27e-05	0.00105	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—CXCL8—uterine cancer	6.24e-05	0.00104	CbGpPWpGaD
Vidarabine—ADA—Metabolism—EP300—uterine cancer	5.98e-05	0.000998	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—SMAD3—uterine cancer	5.9e-05	0.000984	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—CXCL8—uterine cancer	5.67e-05	0.000947	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—FGFR2—uterine cancer	5.62e-05	0.000939	CbGpPWpGaD
Vidarabine—ADK—Metabolism—AKT1—uterine cancer	5.32e-05	0.000888	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ESR1—uterine cancer	4.81e-05	0.000803	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—NRAS—uterine cancer	4.55e-05	0.000759	CbGpPWpGaD
Vidarabine—ADA—Metabolism—PIK3CA—uterine cancer	4.42e-05	0.000739	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CCL2—uterine cancer	4.24e-05	0.000707	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—PIK3CA—uterine cancer	3.96e-05	0.000661	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—KRAS—uterine cancer	3.92e-05	0.000654	CbGpPWpGaD
Vidarabine—ADA—Metabolism—AKT1—uterine cancer	3.61e-05	0.000603	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—PIK3CA—uterine cancer	3.6e-05	0.0006	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—ERBB2—uterine cancer	3.53e-05	0.00059	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CXCL8—uterine cancer	3.35e-05	0.000559	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—HRAS—uterine cancer	3.33e-05	0.000556	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CDKN1B—uterine cancer	3.27e-05	0.000546	CbGpPWpGaD
Vidarabine—ADORA2A—GPCR downstream signaling—AKT1—uterine cancer	3.24e-05	0.00054	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—CTNNB1—uterine cancer	3.09e-05	0.000516	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PTEN—uterine cancer	3.01e-05	0.000503	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling by GPCR—AKT1—uterine cancer	2.94e-05	0.000491	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—EP300—uterine cancer	2.87e-05	0.000479	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—VEGFA—uterine cancer	2.72e-05	0.000454	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—NRAS—uterine cancer	2.69e-05	0.000449	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—KRAS—uterine cancer	2.31e-05	0.000386	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—PIK3CA—uterine cancer	2.12e-05	0.000355	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—TP53—uterine cancer	2.06e-05	0.000343	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—HRAS—uterine cancer	1.97e-05	0.000328	CbGpPWpGaD
Vidarabine—ADORA2A—Signaling Pathways—AKT1—uterine cancer	1.74e-05	0.00029	CbGpPWpGaD
